Hetero Biopharma gets CDSCO panel nod to market, manufacture Tenecteplase Susmita Roy29 Dec 2022 5:43 PM ISTNew Delhi: Pharma major Hetero Biopharma has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drugs Standard...
Percutaneous closure of post myocardial infarction ventricular septal rupture Dr. Nandita Mohan7 Sept 2022 9:15 AM ISTThe incidence of post-infarction ventricular septum rupture has decreased from 1–2% to 0.25–0.31%. Survival up to 1 month without intervention is 6%....
Thrombolytic therapy with tenecteplase increased early reperfusion in mobile stroke units: Lancet Jacinthlyn Sylvia1 July 2022 11:15 AM ISTAustralia: A new study conducted by Andrew Bivard and his team shows that tenecteplase treatment on the mobile stroke units (MSUs) resulted in a...
Thrombolysis by slow infusion of t-PA effective in prosthetic valve thrombosis: Study Medha Baranwal22 April 2022 9:00 AM ISTTurkey: Low-dose and slow/ultraslow infusion of tissue plasminogen activator (t-PA) should be considered a viable treatment in patients with...
Thrombolysis Bests Surgery In Most Cases Of Obstructive Mechanical Valve Thrombosis MD Bureau22 March 2022 9:00 AM ISTThrombotic obstruction is an uncommon but important late complication of prosthetic heart valves, and with older prosthesis models with a single...
Thrombolytic therapy safe for people with ischemic stroke even if they have unruptured aneurysms: AAN study Hina Zahid7 Oct 2021 9:29 PM ISTMINNEAPOLIS -A new study finds that Thrombolytic therapy may be safe for people with ischemic stroke even if they have unruptured aneurysms.The study...
Indigo aspiration system shows promising results for pulmonary embolism: EXTRACT-PE Trial dr. Abhimanyu Uppal17 Jan 2021 6:45 PM ISTManagement of sub-massive pulmonary embolism (PE), defined by normal blood pressure but right ventricular (RV) dysfunction, is marred by uncertainty....
Shorter door-to-needle time lowers mortality, readmission in stroke: JAMA Medha Baranwal18 Aug 2020 8:46 PM ISTUSA: Shorter door-to-needle times in stroke patients (aged 65 years or older) treated with tissue plasminogen activator (tPA), lowers...
